Dogwood Therapeutics

DWTX

Market cap $57.2M

ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.

Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026 Veteran Biopharma Executive and Venture Investor to Lead Newly Formed Dogwood Advisory Board in advance of Halneuron® Phase 2b Data Which is Projected for Fall of 2026

Dogwood Therapeutics, Inc. (DWTX) Shareholder/Analyst Call Prepared Remarks Transcript

New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package

- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -

ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders.

- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royalty up to 15% on Net Sales - - Dogwood Entitled to a Percentage of Future Development and Regulatory Milestones, as well as 9% of Future Capital Raised by PRIDCor to Advance Development of IMC-1 and IMC-2 - ALPHARETTA, Ga., April 23, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization partnership with PRIDCor Therapeutics, LLC (“PRIDCor”), a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long-COVID, for Dogwood's anti-viral candidates, IMC-1 and IMC-2.

Dogwood  licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”, “Dogwood” or “the Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced FDA acceptance of an Investigational New Drug (“IND”) application for its development candidate SP16, administered intravenously (“IV”), for the treatment of chemotherapy-induced pain and peripheral neuropathy (“CIPPN”).

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025.

- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain (“HALT-CINP”) trial. HALT-CINP remains on track for top line results to be available during the third quarter of 2026.